Ulcerative colitis.
@article{Danese2011UlcerativeC, title={Ulcerative colitis.}, author={Silvio Danese and Claudio Fiocchi}, journal={The New England journal of medicine}, year={2011}, volume={365 18}, pages={ 1713-25 } }
Is medical clearance required? .................................. Possibly (e.g., if the disease is unstable — flare-up — and/or there are active oral lesions). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/increased risk of infection (e.g., corticosteroids [e.g., prednisone], azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, sulfasalazine, biologic response modifier drugs [e.g., anti-tumour necrosis…
349 Citations
Biological Agents for Moderately to Severely Active Ulcerative Colitis
- MedicineAnnals of Internal Medicine
- 2014
A systematic review of randomized, controlled trials assessing biological agents as induction or maintenance therapy for moderately to severely active UC in adults to address this issue and compare the different treatment options.
Positioning therapies in ulcerative colitis.
- Biology, MedicineClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
- 2020
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
- Medicine, BiologyArquivos de gastroenterologia
- 2018
A patient with active ulcerative colitis with primary non-response to three biologics, with different mechanisms of action, who refused surgical treatment and had a favorable response to tofacitinib with clinical and endoscopic remission is reported.
Immunosuppressive and biologic therapy for ulcerative colitis
- MedicineExpert opinion on emerging drugs
- 2012
There is a need for optimizing and renewing the traditional therapeutic approach to UC, and new therapies beyond conventional treatment options possibly aiming to change the poor clinical course of many patients with ulcerative colitis.
Inflammatory bowel disease and targeted oral anti-TNFα therapy.
- Biology, MedicineAdvances in protein chemistry and structural biology
- 2020
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
- Medicine, BiologyTherapeutic advances in gastroenterology
- 2017
Data is summarized regarding AJM300, phosphatidylcholine (LT-02), mongersen, ozanimod, filgotinib and tofacitinib, which were tested in clinical trials for both Crohn’s disease and ulcerative colitis.
Inflammatory pathways of importance for management of inflammatory bowel disease.
- Medicine, BiologyWorld journal of gastroenterology
- 2014
The major signaling pathways of clinical importance for IBD therapy are elucidated and several new treatment options are under development for the treatment of CD and UC, however, no drug fits all patients.
Ulcerative Colitis: Update on Medical Management
- MedicineCurrent Gastroenterology Reports
- 2015
The recent publication of the SCENIC consensus statement on surveillance and management of Dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia and new biologics, including those targeting the Janus tyrosine kinase (JAK) pathway are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies.
Skin Manifestations of Inflammatory Bowel Disease
- MedicineClinical Reviews in Allergy & Immunology
- 2017
Current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options are summarized.
References
SHOWING 1-10 OF 104 REFERENCES
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?
- MedicineThe American Journal of Gastroenterology
- 2011
Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment, and there are insufficient data to make recommendations on when to stop anti-TNF therapy.
Exacerbation of ulcerative colitis after rituximab salvage therapy
- Medicine, BiologyInflammatory bowel diseases
- 2007
The data suggest an important anti‐ rather than proinflammatory role of B‐cells in UC, which is in contrast to rheumatoid arthritis patients, rituximab had deleterious effects in this UC patient by blocking IL‐10 producing B‐ cells.
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
- MedicineJournal of Crohn's & colitis
- 2009
Biological therapies for inflammatory bowel diseases.
- Medicine, BiologyGastroenterology
- 2009
Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment of patients with Crohn's disease and ulcerative colitis and has achieved treatment goals such as mucosal healing and decreasing the need for hospitalizations and surgeries.
European evidence-based Consensus on the management of ulcerative colitis: Current management.
- MedicineJournal of Crohn's & colitis
- 2008
Diagnostic Standards in the Pathology of Inflammatory Bowel Disease
- MedicineDigestive Diseases
- 2009
A high degree of awareness by clinicians and pathologists is required in order to miss these life-threatening complications of IBD, and the use of modern immunosuppressive therapies may go along with an increased susceptibility towards infections.
Colectomy rate in acute severe ulcerative colitis in the infliximab era.
- MedicineDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
- 2008
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
- MedicineNature Clinical Practice Gastroenterology &Hepatology
- 2004
The diagnosis of ulcerative colitis is being aided by recent advances in diagnostic strategies, including the detection of fecal and serologic markers and the use of wireless capsule endoscopy, but, in the absence of a pathognomonic marker, the definition of this disease remains undefined.
Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production
- Medicine, BiologyGut
- 2010
The data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies.